The controversy over the so-called pay-to-delay settlements is bubbling up to the U.S. Supreme Court, Pharmalot reports. Three pharmacy chains and a wholesaler have asked the court to review the issue because they maintain the deals choke off competition by stifling the arrival of lower-cost generics to their shelves. Report